The ins and outs of mitochondrial dysfunction in NASH - PubMed (original) (raw)
Review
The ins and outs of mitochondrial dysfunction in NASH
B Fromenty et al. Diabetes Metab. 2004 Apr.
Abstract
Rich diet and lack of exercise are causing a surge in obesity, insulin resistance and steatosis, which can evolve into steatohepatitis. Steatosis and nonalcoholic steatohepatitis (NASH) can also be induced by drugs such as amiodarone, tamoxifen and some antiretroviral drugs. There is growing evidence that mitochondrial dysfunction, and more specifically respiratory chain deficiency, plays a role in the pathophysiology of NASH whatever its initial cause. In contrast, the B-oxidation of fatty acids can be either increased (as in insulin resistance-associated NASH) or decreased (as in drug-induced NASH). However, in both circumstances, the generation of reactive oxygen species (ROS) by the damaged respiratory chain is augmented, as components of this chain are over-reduced by electrons, which then abnormally react with oxygen to form increased amounts of ROS. Concomitantly, ROS oxidize fat deposits to release lipid peroxidation products that have detrimental effects on hepatocytes and other hepatic cells. In hepatocytes, ROS and lipid peroxidation products further impair the respiratory chain, either directly or indirectly through oxidative damage to the mitochondrial genome. This, in turn, leads to the generation of more ROS and a vicious cycle ensues. Mitochondrial dysfunction can also lead to apoptosis or necrosis depending on the energy status of the cell. ROS and lipid peroxidation products also activate stellate cells, thus resulting in fibrosis. Finally, ROS and lipid peroxidation increase the generation of several cytokines (TNF-alpha, TGF-B, Fas ligand) that play sundry roles in the pathogenesis of NASH. Recent investigations have shown that some genetic polymorphisms can significantly increase the risk of steatohepatitis and that several drugs can prevent or even reverse NASH. For the next decade, reducing the incidence of NASH will be a major challenge for hepatologists.
Similar articles
- Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it.
Begriche K, Igoudjil A, Pessayre D, Fromenty B. Begriche K, et al. Mitochondrion. 2006 Feb;6(1):1-28. doi: 10.1016/j.mito.2005.10.004. Epub 2006 Jan 5. Mitochondrion. 2006. PMID: 16406828 Review. - Mitochondrial injury in steatohepatitis.
Pessayre D, Fromenty B, Mansouri A. Pessayre D, et al. Eur J Gastroenterol Hepatol. 2004 Nov;16(11):1095-105. doi: 10.1097/00042737-200411000-00003. Eur J Gastroenterol Hepatol. 2004. PMID: 15489566 Review. - Role of mitochondria in non-alcoholic fatty liver disease.
Pessayre D. Pessayre D. J Gastroenterol Hepatol. 2007 Jun;22 Suppl 1:S20-7. doi: 10.1111/j.1440-1746.2006.04640.x. J Gastroenterol Hepatol. 2007. PMID: 17567459 Review. - Mitochondria in steatohepatitis.
Pessayre D, Berson A, Fromenty B, Mansouri A. Pessayre D, et al. Semin Liver Dis. 2001;21(1):57-69. doi: 10.1055/s-2001-12929. Semin Liver Dis. 2001. PMID: 11296697 Review. - Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis.
Pessayre D, Mansouri A, Fromenty B. Pessayre D, et al. Am J Physiol Gastrointest Liver Physiol. 2002 Feb;282(2):G193-9. doi: 10.1152/ajpgi.00426.2001. Am J Physiol Gastrointest Liver Physiol. 2002. PMID: 11804839 Review.
Cited by
- In vitro treatment of HepG2 cells with saturated fatty acids reproduces mitochondrial dysfunction found in nonalcoholic steatohepatitis.
García-Ruiz I, Solís-Muñoz P, Fernández-Moreira D, Muñoz-Yagüe T, Solís-Herruzo JA. García-Ruiz I, et al. Dis Model Mech. 2015 Feb;8(2):183-91. doi: 10.1242/dmm.018234. Epub 2014 Dec 24. Dis Model Mech. 2015. PMID: 25540128 Free PMC article. - Curative role of natural PPARγ agonist in non-alcoholic fatty liver disease (NAFLD).
Singh S, Kumar A, Gupta S, Agrawal R. Singh S, et al. Tissue Barriers. 2024 Jul 2;12(3):2289830. doi: 10.1080/21688370.2023.2289830. Epub 2023 Dec 5. Tissue Barriers. 2024. PMID: 38050958 Free PMC article. Review. - Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression.
Zhang Q, Lou Y, Bai XL, Liang TB. Zhang Q, et al. World J Gastroenterol. 2018 Aug 21;24(31):3500-3512. doi: 10.3748/wjg.v24.i31.3500. World J Gastroenterol. 2018. PMID: 30131656 Free PMC article. Review. - Metabolic-Associated Fatty Liver Disease: The Influence of Oxidative Stress, Inflammation, Mitochondrial Dysfunctions, and the Role of Polyphenols.
Tauil RB, Golono PT, de Lima EP, de Alvares Goulart R, Guiguer EL, Bechara MD, Nicolau CCT, Yanaguizawa Junior JL, Fiorini AMR, Méndez-Sánchez N, Abenavoli L, Direito R, Valente VE, Laurindo LF, Barbalho SM. Tauil RB, et al. Pharmaceuticals (Basel). 2024 Oct 10;17(10):1354. doi: 10.3390/ph17101354. Pharmaceuticals (Basel). 2024. PMID: 39458995 Free PMC article. Review. - Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine.
Noureddin M, Mato JM, Lu SC. Noureddin M, et al. Exp Biol Med (Maywood). 2015 Jun;240(6):809-20. doi: 10.1177/1535370215579161. Epub 2015 Apr 13. Exp Biol Med (Maywood). 2015. PMID: 25873078 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous